Table 1.
Patients demographics and baseline characteristics.
| Patient Population | |
|---|---|
| n = 33 | |
| Age (Years) | 57 (30–74) |
| ECOG | |
| 0 | 26 (%79) |
| 1–2 | 7 (%21) |
| Women | 8 (%24) |
| Ethic origin | |
| White | 33 (%100) |
| Asian | 0 (%0) |
| Black | 0 (%0) |
| Positive family history for oncological diseases | 7 (%21) |
| Second tumor disease | 4 (%12) |
| Nicotiabusus | 14 (%42) |
| Primary tumor side | |
| Stomach | 11 (%33) |
| GEJ | 22 (%67) |
| Extend of disease at study entry | |
| Locally advanced | 2 (%6) |
| Metastatic | 31 (%94) |
| Metastatic sites per patient | |
| 1 | 15 (%45) |
| 2 | 12 (%36) |
| 3–4 | 4 (%12) |
| Chemothrapy regimen | |
| TOGA | 23 (%70) |
| Trastuzumab mono | 3 (%9) |
| DCF | 2 (%6) |
| EOX | 2 (%6) |
| FOLFOX | 2 (%6) |
| FOLFIRI | 1 (%3) |
| Previous radiationtherapy | 4 (%12) |
| Previous gastrectomy | 16 (%48) |
| Herceptin line | |
| 1st | 23 (%70) |
| 2nd | 7 (%21) |
| 3rd | 3 (%9) |
| Previous chemotherapy | |
| EOX | 4 (%12) |
| DCF | 3 (%9) |
| HER2 status | |
| ICH 3+ | 32 (%97) |
| ICH 2+/FISH pos | 1 (%3) |
ECOG, Eastern Cooperative Oncology Groups; GEJ, gastroesophageal junction; ToGA, trastuzumab for gastric cancer; DCF, docetaxel/cisplatin/5-fluoroucil; EOX, epirubicin/oxaliplatin/capecitabine; FOLFOX, 5-fluoroucil/oxaliplatin; FOLFIRI, 5-fluoroucil/irinotecan; HER2, human epidermal growth factor receptor 2; ICH, immunohistochemistry; FISH, fluorescence in situ hybridization